GeoVax Labs, Inc. has embarked on a pioneering research program to assess the immunogenicity and stability of its GEO-MVA vaccine when delivered through Vaxxas’ high-density microarray patch (HD-MAP) technology. This study, conducted at the University of Queensland, seeks to validate a needle-free, self-administered vaccine platform that could revolutionize pandemic preparedness and global immunization efforts. The...
Author: News Desk (News Desk)
HealthLynked Corp. Enhances Healthcare Solutions with New Website and Provider Directory Upgrades
HealthLynked Corp. (OTCQB: HLYK), a leader in healthcare technology, has unveiled its newly designed Enterprise Healthcare Solutions Website, www.hlykgroup.com, alongside significant upgrades to its national provider directory. This initiative marks a pivotal step in the company’s mission to streamline healthcare services and enhance patient-provider interactions. The updated platform is designed to serve as a comprehensive...
GeoVax Advances Needle-Free Vaccine Technology with HD-MAP Study
GeoVax Labs, Inc. has embarked on a pioneering research program to assess the immunogenicity and stability of its GEO-MVA vaccine when delivered through Vaxxas’ high-density microarray patch (HD-MAP) technology. This study, conducted at the University of Queensland, seeks to validate a needle-free, self-administered vaccine platform that could revolutionize pandemic preparedness and global immunization efforts. The...
Metavesco Expands Digital Asset Strategy with Ethereum Acquisition
Metavesco, Inc. (OTC: MVCO), a publicly traded diversified holding company, has strategically acquired 28 Ethereum (ETH) at an average price of $3,595, marking a significant expansion of its digital asset strategy. While Bitcoin continues to serve as the company’s foundational long-term reserve asset, Ethereum has been introduced as a high-conviction, opportunistic position. This decision reflects...
Dropzone AI Secures $37M Series B Funding to Revolutionize Cybersecurity with AI SOC Analysts
Dropzone AI, a pioneer in AI SOC analysts, has successfully raised $37 million in Series B funding, with Theory Ventures leading the investment round. This significant financial boost highlights the industry’s recognition of Dropzone AI’s innovative approach to cybersecurity, leveraging AI to autonomously triage and investigate security alerts with human-level reasoning. The funding round also...
Dropzone AI Secures $37M Series B Funding to Revolutionize Cybersecurity with AI SOC Analysts
Dropzone AI, a pioneer in AI SOC analysts, has successfully raised $37 million in Series B funding, with Theory Ventures leading the investment round. This significant financial boost highlights the industry’s recognition of Dropzone AI’s innovative approach to cybersecurity, leveraging AI to autonomously triage and investigate security alerts with human-level reasoning. The funding round also...
A. Aubrey Bodine’s Legacy: Capturing the Essence of the Early 20th Century Through Photography
A. Aubrey Bodine, celebrated as one of the twentieth century’s finest pictorialists, left an indelible mark on the world of photography with his remarkable documentary pictures. His career, which began in 1923 with the Baltimore Sunday Sun, spanned 47 years, during which he captured the essence of Maryland’s myriad occupations and activities. Bodine’s work stood...
A. Aubrey Bodine’s Legacy: Capturing the Essence of the Early 20th Century Through Photography
A. Aubrey Bodine, celebrated as one of the twentieth century’s finest pictorialists, left an indelible mark on the world of photography with his remarkable documentary pictures. His career, which began in 1923 with the Baltimore Sunday Sun, spanned 47 years, during which he captured the essence of Maryland’s myriad occupations and activities. Bodine’s work stood...
Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Optimize Market Dynamics
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has announced a 1-for-12 reverse stock split of its common stock, set to take effect on August 5, 2025. This strategic move, approved by shareholders on July 9 and ratified by the board on July 11, is designed to optimize market dynamics, broaden investor appeal,...
Calidi Biotherapeutics Announces 1-for-12 Reverse Stock Split to Optimize Market Dynamics
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage biotechnology company, has announced a 1-for-12 reverse stock split of its common stock, set to take effect on August 5, 2025. This strategic move, approved by shareholders on July 9 and ratified by the board on July 11, is designed to optimize market dynamics, broaden investor appeal,...